HCV

Idenix Pharmaceuticals has entered into a non-exclusive collaboration with Janssen Pharmaceuticals to commence Phase II all-oral combination studies evaluating IDX719, simeprevir (TMC435) and TMC647055 for the treatment of hepatitis C virus (HCV).

The collaboration will focus on the clinical development of direct-acting antiviral (DAA) HCV combination therapies.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Idenix president and chief executive officer Ron Renaud said the company is looking forward to initiating a Phase II study in the first quarter of 2013.

"This will allow us to achieve a key goal of ours for 2013, which is to advance the development of IDX719 as part of all-oral HCV combinations in two- and three-drug regimens," Renaud said.

IDX719 is Idenix’s once-daily pangenotypic NS5A inhibitor, and simeprevir (TMC435) is a once-daily protease inhibitor jointly developed by Janssen and Medivir.

TMC647055, a once-daily non-nucleoside polymerase inhibitor being developed by Janssen, is boosted with low-dose ritonavir.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to the agreement, an initial drug-drug interaction study is expected to commence in the first quarter of 2013 subsequent to which Phase II studies will be conducted, all pending regulatory approvals.

The Phase II programme is designed to initially assess the two-DAA combination of IDX719 and simeprevir along with ribavirin for 12 weeks in HCV-infected patients new to the treatment.

Later a three-DAA combination of IDX719, simeprevir and TMC647055/r, with and without ribavirin, will be evaluated.

Idenix will conduct the clinical trials while both companies preserve all rights to their respective compounds under the deal.

Image: Electron micrographs of hepatitis C virus purified from cell culture. Scale bar is 50 nanometers. Photo: Courtesy of the Center for the Study of Hepatitis C, The Rockefeller University.